Use of Flibanserin in the treatment of chronic pain

• US 20060258640A1
• Filed: 05/04/2006
• Published: 11/16/2006
• Est. Priority Date: 05/13/2005
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: BORSINI, Franco, GAIDA, Wolfram, CECI, Angelo
• Application Number:
  US11/381,590
• Publication Number:
  US 20060258640A1
• Time in Patent Office: Days
• US Class Current: 514/217
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for the treatment of chronic pain comprising the administration of a therapeutically effective amount of flibanserin

Claims

1. ) A pharmaceutical composition comprising flibanserin 1, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or solvate thereof, or a combination thereof, as one active ingredient in combination with at least one second active ingredient 2, which second active ingredient is effective in the treatment of chronic pain.

2. ) The pharmaceutical composition according to claim 1, wherein the active ingredient 2 is selected from the group consisting of opioids 2a, anticonvulsants 2b, antidepressants 2c, non-stereoidal antiflammatory drugs 2d, local anesthetics 2e, and combinations thereof.

3. ) The pharmaceutical composition according to claim 2, wherein the opioid 2a is selected from the group consisting of morphin, tramadol and buprenorphin, in form of a pharmaceutically acceptable acid addition salt, in form of a hydrate or solvate or in the form of an individual optical isomer, a mixture of the individual enantiomers, or a racemates thereof, or a combination thereof.

4. ) The pharmaceutical compositions according to claim 2, comprising a therapeutically effective amount of flibanserin 1 and a therapeutically effective amount of one or more anticonvulsant 2b.

5. ) The pharmaceutical compositions according to claim 4, wherein the anticonvulsant 2b is selected from the group consisting of gabapentin, carbamazepine, phenytoin, or combinations thereof.

6. ) The pharmaceutical compositions according to claim 2, comprising a therapeutically effective amount of flibanserin 1 and a therapeutically effective amount of one or more antidepressant 2c.

7. ) The pharmaceutical compositions according to claim 6, wherein the antidepressant 2c is selected from the group consisting of paroxetine, citalopram, amitriptyline, or combinations thereof.

8. ) The pharmaceutical composition according to claim 2, comprising a therapeutically effective amount of flibanserin 1 and a therapeutically effective amount of one or more non-stereoidal antiflammatory drug 2d.

9. ) The pharmaceutical compositions according to claim 8, wherein the non-stereoidal antiflammatory drug 2d is selected from the group consisting of meloxicam, diclofenac, ibuprofen, or combinations thereof.

10. ) The pharmaceutical composition according to claim 2, comprising a therapeutically effective amount of flibanserin 1 and a therapeutically effective amount of one or more local anesthetic 2e.

11. ) The pharmaceutical composition according to claim 10, wherein the local anesthetic 2e is selected from the group consisting of lidocaine, mexiletine, or combinations thereof.

12. ) A method for the treatment of chronic pain comprising the administration of a therapeutically effective amount of flibanserin 1, in form of the free base, a pharmacologically acceptable acid addition salt or in form of the hydrate or solvate thereof, or a combination thereof.

13. ) A method for the treatment of chronic pain comprising the administration of a therapeutically effective amount of flibanserin 1, in form of the free base, a pharmacologically acceptable acid addition salt or in form of a hydrate or a solvate thereof, in combination with a therapeutically effective amount of another active ingredient 2, which another active ingredient is effective in the treatment of chronic pain.

14. ) The method according to claim 13, wherein 2 is selected from the group consisting of opioids 2a, anticonvulsants 2b, antidepressants 2c, non-stereoidal antiflammatory drugs 2d, local anesthetics 2e, and combinations thereof.